{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:03:11Z","timestamp":1794726191679,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:00:00Z","timestamp":1288742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Simple, non-invasive tests for early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers for the early diagnosis of Alzheimer disease (AD) are available. The clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. A biochemical marker that would support the clinical diagnosis and distinguish AD from other causes of dementia would therefore be of great value as a screening test. A total of 126 samples were obtained from subjects with AD, and age-sex-matched controls. Additionally, 51 Parkinson's disease (PD) patients were used as an example of another neurodegenerative disorder. We analyzed saliva and plasma levels of \u03b2 amyloid (A\u03b2) using a highly sensitive ELISA kit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found a small but statistically significant increase in saliva A\u03b2<jats:sub>42<\/jats:sub> levels in mild AD patients. In addition, there were not differences in saliva concentration of A\u03b2<jats:sub>42<\/jats:sub> between patients with PD and healthy controls. Saliva A\u03b2<jats:sub>40<\/jats:sub> expression was unchanged within all the studied sample. The association between saliva A\u03b2<jats:sub>42<\/jats:sub> levels and AD was independent of established risk factors, including age or Apo E, but was dependent on sex and functional capacity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We suggest that saliva A\u03b2<jats:sub>42<\/jats:sub> levels could be considered a potential peripheral marker of AD and help discrimination from other types of neurodegenerative disorders. We propose a new and promising biomarker for early AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-10-108","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T19:30:10Z","timestamp":1288812610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study"],"prefix":"10.1186","volume":"10","author":[{"given":"Felix","family":"Bermejo-Pareja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Antequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teo","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Carro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrn1435","volume":"10","author":"PT Lansbury Jr","year":"2004","unstructured":"Lansbury PT: Back to the future: the old-fashioned way to new medications for neurodegeneration. Nat Med. 2004, 10: 51-57. 10.1038\/nrn1435.","journal-title":"Nat Med"},{"key":"389_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1096\/fsb2fasebj.12.1.17","volume":"12","author":"L Gasparini","year":"1998","unstructured":"Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S: Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J. 1998, 12: 17-34.","journal-title":"FASEB J"},{"key":"389_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JAD-2005-7208","volume":"7","author":"J Attems","year":"2005","unstructured":"Attems J, Lintner F, Jellinger KA: Olfactory involvement in aging and Alzheimer's disease: an autopsy study. J Alzheimers Dis. 2005, 7: 149-157.","journal-title":"J Alzheimers Dis"},{"key":"389_CR4","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1074\/jbc.271.17.10169","volume":"271","author":"PH Frederikse","year":"1996","unstructured":"Frederikse PH, Garland D, Zigler JS, Piatigorsky J: Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem. 1996, 271: 10169-10174. 10.1074\/jbc.271.17.10169.","journal-title":"J Biol Chem"},{"key":"389_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1365-2613.2000.00156.x","volume":"81","author":"K Fukuchi","year":"2000","unstructured":"Fukuchi K, Li L, Hart M, Lindsey JR: Accumulation of amyloid-beta protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor. Int J Exp Pathol. 2000, 81: 231-239. 10.1046\/j.1365-2613.2000.00156.x.","journal-title":"Int J Exp Pathol"},{"key":"389_CR6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1096\/fj.04-2022fje","volume":"19","author":"MM Sousa","year":"2005","unstructured":"Sousa MM, do Amaral JB, Guimar\u00e3es A, Saraiva MJ: Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J. 2005, 19: 124-126.","journal-title":"FASEB J"},{"key":"389_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1152\/ajpcell.00508.2005","volume":"291","author":"YS Oh","year":"2006","unstructured":"Oh YS, Turner RJ: Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. Am J Physiol Cell Physiol. 2006, 291: 76-82. 10.1152\/ajpcell.00508.2005.","journal-title":"Am J Physiol Cell Physiol"},{"key":"389_CR8","first-page":"208","volume":"5","author":"A Scherber","year":"1980","unstructured":"Scherber A, Richter K, Schaps P: Distribution of antiepileptic drugs between plasma, plasma water, cerebrospinal fluid, saliva and brain. Monogr Neural Sci. 1980, 5: 208-212.","journal-title":"Monogr Neural Sci"},{"key":"389_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clinbiochem.2003.10.007","volume":"37","author":"R Sayer","year":"2004","unstructured":"Sayer R, Law E, Connelly PJ, Breen KC: Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors. Clin Biochem. 2004, 37: 98-104. 10.1016\/j.clinbiochem.2003.10.007.","journal-title":"Clin Biochem"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2: 605-613. 10.1016\/S1474-4422(03)00530-1.","journal-title":"Lancet Neurol"},{"key":"389_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007, 13: 1359-1362. 10.1038\/nm1653.","journal-title":"Nat Med"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.biopha.2007.05.009","volume":"61","author":"DC German","year":"2007","unstructured":"German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP: Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother. 2007, 61: 383-389. 10.1016\/j.biopha.2007.05.009.","journal-title":"Biomed Pharmacother"},{"key":"389_CR13","volume-title":"DSM-IV. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington DC: American Psychiatric Association"},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34: 939-944.","journal-title":"Neurology"},{"key":"389_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR: \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ana.410320721","volume":"32","author":"DB Calne","year":"1992","unstructured":"Calne DB, Snow BJ, Lee C: Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992, 32: 125-127. 10.1002\/ana.410320721.","journal-title":"Ann Neurol"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol. 1999, 56: 33-39. 10.1001\/archneur.56.1.33.","journal-title":"Arch Neurol"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2114\/jpa2.25.91","volume":"25","author":"SA Decker","year":"2006","unstructured":"Decker SA: Low salivary cortisol and elevated depressive affect among rural men in Botswana: reliability and validity of laboratory results. J Physiol Anthropol. 2006, 25: 91-101. 10.2114\/jpa2.25.91.","journal-title":"J Physiol Anthropol"},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/gps.1882","volume":"23","author":"PF Boston","year":"2008","unstructured":"Boston PF, Gopalkaje K, Manning L, Middleton L, Loxley M: Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study. Int J Geriatr Psychiatry. 2008, 23: 439-440. 10.1002\/gps.1882.","journal-title":"Int J Geriatr Psychiatry"},{"key":"389_CR20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/clinchem\/45.7.1094","volume":"45","author":"C Aslanidis","year":"1999","unstructured":"Aslanidis C, Schmitz G: High-speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. Clin Chem. 1999, 45: 1094-1097.","journal-title":"Clin Chem"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1074\/jbc.M507705200","volume":"281","author":"C Yao","year":"2006","unstructured":"Yao C, Karabasil MR, Purwanti N, Li X, Akamatsu T, Kanamori N, Hosoi K: Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J Biol Chem. 2006, 281: 7968-7976. 10.1074\/jbc.M507705200.","journal-title":"J Biol Chem"},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/hmg\/ddg322","volume":"12","author":"EJ Lehman","year":"2003","unstructured":"Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT: Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003, 12: 2949-2956. 10.1093\/hmg\/ddg322.","journal-title":"Hum Mol Genet"},{"key":"389_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archneurol.2008.565","volume":"66","author":"W Xia","year":"2009","unstructured":"Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ: A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009, 66: 190-199. 10.1001\/archneurol.2008.565.","journal-title":"Arch Neurol"},{"key":"389_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1602\/neurorx.1.2.226","volume":"1","author":"MC Irizarry","year":"2004","unstructured":"Irizarry MC: Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004, 1: 226-234. 10.1602\/neurorx.1.2.226.","journal-title":"NeuroRx"},{"key":"389_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1586\/14737159.5.5.661","volume":"5","author":"K Blennow","year":"2005","unstructured":"Blennow K: CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn. 2005, 5: 661-672. 10.1586\/14737159.5.5.661.","journal-title":"Expert Rev Mol Diagn"},{"key":"389_CR26","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006, 129: 3035-3041. 10.1093\/brain\/awl269.","journal-title":"Brain"},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5: 228-234. 10.1016\/S1474-4422(06)70355-6.","journal-title":"Lancet Neurol"},{"key":"389_CR28","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/brain\/awm140","volume":"130","author":"K Buerger","year":"2007","unstructured":"Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H: No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2007, 130: e82-10.1093\/brain\/awm140.","journal-title":"Brain"},{"key":"389_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0031-9384(01)00658-8","volume":"75","author":"CJ Cook","year":"2002","unstructured":"Cook CJ: Rapid noninvasive measurement of hormones in transdermal exudate and saliva. Physiol Behav. 2002, 75: 169-181. 10.1016\/S0031-9384(01)00658-8.","journal-title":"Physiol Behav"},{"key":"389_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126\/science.1072994.","journal-title":"Science"},{"key":"389_CR31","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003, 289: 2094-2103. 10.1001\/jama.289.16.2094.","journal-title":"JAMA"},{"key":"389_CR32","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.neurobiolaging.2007.01.008","volume":"29","author":"MO Dietrich","year":"2008","unstructured":"Dietrich MO, Spuch C, Antequera D, Rodal I, de Y\u00e9benes JG, Molina JA, Bermejo F, Carro E: Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging. 2008, 29: 902-912. 10.1016\/j.neurobiolaging.2007.01.008.","journal-title":"Neurobiol Aging"},{"key":"389_CR33","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"LE Goldstein","year":"2003","unstructured":"Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI: Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet. 2003, 361: 1258-1265. 10.1016\/S0140-6736(03)12981-9.","journal-title":"Lancet"},{"key":"389_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttil\u00e4 T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000, 57: 100-105. 10.1001\/archneur.57.1.100.","journal-title":"Arch Neurol"},{"key":"389_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995, 38: 643-648. 10.1002\/ana.410380413.","journal-title":"Ann Neurol"},{"key":"389_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0022-510X(96)00314-0","volume":"148","author":"A Tamaoka","year":"1997","unstructured":"Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, Hirai S, Furiya Y, Endoh R, Mori H: Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997, 148: 41-45. 10.1016\/S0022-510X(96)00314-0.","journal-title":"J Neurol Sci"},{"key":"389_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archneur.55.7.937","volume":"55","author":"D Galasko","year":"1998","unstructured":"Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998, 55: 937-945. 10.1001\/archneur.55.7.937.","journal-title":"Arch Neurol"},{"key":"389_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1212\/WNL.52.3.547","volume":"52","author":"SC Samuels","year":"1999","unstructured":"Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL: CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology. 1999, 52: 547-551.","journal-title":"Neurology"},{"key":"389_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/geronj\/45.2.M61","volume":"45","author":"JA Ship","year":"1990","unstructured":"Ship JA, DeCarli C, Friedland RP, Baum BJ: Diminished submandibular salivary flow in dementia of the Alzheimer type. J Gerontol. 1990, 45: 61-66.","journal-title":"J Gerontol"},{"key":"389_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/1097-0029(20010101)52:1<65::AID-JEMT9>3.0.CO;2-4","volume":"52","author":"A Chodobski","year":"2001","unstructured":"Chodobski A, Szmydynger-Chodobska J: Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech. 2001, 52: 65-82. 10.1002\/1097-0029(20010101)52:1<65::AID-JEMT9>3.0.CO;2-4.","journal-title":"Microsc Res Tech"},{"key":"389_CR41","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/nm1202-793","volume":"8","author":"E Carro","year":"2002","unstructured":"Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002, 8: 1390-1397. 10.1038\/nm793.","journal-title":"Nat Med"},{"key":"389_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0006-8993(99)02315-X","volume":"853","author":"I Ray","year":"2000","unstructured":"Ray I, Chauhan A, Wegiel J, Chauhan VP: Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 2000, 853: 344-351. 10.1016\/S0006-8993(99)02315-X.","journal-title":"Brain Res"},{"key":"389_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/323455a0","volume":"323","author":"DJ Kwiatkowski","year":"1986","unstructured":"Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL: Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature. 1986, 323: 455-458. 10.1038\/323455a0.","journal-title":"Nature"},{"key":"389_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2008-14102","volume":"14","author":"SF Gloeckner","year":"2008","unstructured":"Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008, 14: 17-25.","journal-title":"J Alzheimers Dis"},{"key":"389_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2009.06.018","volume":"36","author":"D Antequera","year":"2009","unstructured":"Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, Ferrer I, Bermejo-Pareja F, Carro E: Cytoplasmic gelsolin increases mitochondrial activity and reduces A\u03b2 burden in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009, 36: 42-50. 10.1016\/j.nbd.2009.06.018.","journal-title":"Neurobiol Dis"},{"key":"389_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.1471-4159.1996.66010259.x","volume":"66","author":"PC Southwick","year":"1996","unstructured":"Southwick PC, Yamagata SK, Echols CL, Higson GJ, Neynaber SA, Parson RE, Munroe WA: Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996, 66: 259-265. 10.1046\/j.1471-4159.1996.66010259.x.","journal-title":"J Neurochem"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-10-108\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T05:31:19Z","timestamp":1630474279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-10-108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-10-108","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]},"assertion":[{"value":"8 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"108"}}